ClinicalTrials.gg
RecruitingNCT06566170Updated Nov 3, 2026

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

An observational study in Alzheimer Disease, sponsored by Eli Lilly and Company. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Eli Lilly and Company · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,250
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 99 studies in Alzheimer Disease by Eli Lilly and Company — 13 open to participants now, 18 under way, 8 of them phase 3. Alzheimer Disease · Eli Lilly and Company.

Started
2024
with 4 others
Observational
4 of 99
2 open now
Primary completion
2031-05
later than 16 of 17 live
Registered
87th of 99
by date

Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is one of 5 that started in 2024, is one of 4 observational ones, reaches primary completion later than 16 of the 17 other live ones, and was the 87th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

13 of the 99 studies in Alzheimer Disease by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Alzheimer Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of a donanemab plus usual care group and a usual care alone group. Participants will be enrolled 1:2 into donanemab plus usual care and usual care alone groups to allow enough participants in the usual care group to be matched with participants in the donanemab group to enable robust comparative effectiveness analyses.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants

  • are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records [EHR] is required prior to screening)
  • have a Telephone Interview for Cognitive Status (TICS) score of ≥21
  • presence of amyloid beta (Aβ) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid [CSF]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)
  • have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and
  • have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • have prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)
  • have current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., of less than 36 months, requirement for long-term (>12 months) institutional-level care, serious psychiatric illness, etc.)
  • are currently enrolled or intend to enroll in a clinical trial of another product, and
  • have to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Donanemab Group + Usual Care

    Participants will receive open-label (unblinded) donanemab intravenously (IV) and Usual Care

    Drug: Donanemab · Drug: Usual Care

  • Usual Care Group

    Participants will receive usual care.

    Drug: Usual Care

Interventions

  • Administered IV

    Also known as: LY3002813

  • DrugUsual Care

    Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.

06

What researchers measure

Primary outcomes

  1. Time to First Increase in Dependence Level Above Baseline (as derived from the Dependence Scale [DS])

    The DS is a caregiver-reported outcome assessing the need for daily in-home or institutional assistance by participants with AD. The DS is completed as a structured interview with a knowledgeable caregiver or study partner. The scale is composed of 13 items evaluating progressive needs for assistance. The total score ranges from 0 to 15, with higher scores indicating a greater degree of dependence on external support.

    Time frame: Up to 5 Years

Secondary outcomes

  1. Time to Loss of Independence (Dependence Level ≥3 as derived from the DS) for the Subgroup of Participants with Dependence Level <3 at Baseline

    Time frame: Up to 5 Years

  2. Time to Institutionalization from Baseline for the Subgroup of Participants not Institutionalized at Baseline

    Participants who endorse, "Assisted living facility" or "Skilled nursing facility, nursing home, hospice" as their primary residence on the participant lifestyle status Questionnaire (P-LSQ) will be considered institutionalized.

    Time frame: Up to 5 Years

  3. Change from Baseline Over Time (Semi-Annually) in DS Total Score

    Time frame: Baseline, Up to 5 Years

  4. Change from Baseline Over Time (Assessed Semi-Annually) in Functional Assessment Questionnaire (FAQ) Total Score

    The FAQ is a brief, 10-item caregiver-reported outcome measure assessing performance on functional activities impacted early during AD. The maximum total score is 30, with higher scores indicating greater impairment.

    Time frame: Baseline, Up to 5 Years

  5. Change from Baseline Over Time (Assessed Yearly) in Neuropsychiatric Inventory (NPI-Q) Total Severity Score

    The NPI-Q is a brief, caregiver-reported assessment of neuropsychiatric symptoms associated with dementia. The NPI-Q yields total scores for Severity and Distress, reflecting the sum of ratings across all domains, with higher scores indicating a greater degree of symptom severity and caregiver distress, respectively.

    Time frame: Baseline, Up to 5 Years

  6. Change from Baseline Over Time (Assessed Yearly) in Zarit Burden Inventory-short version (ZBI-12) total score

    ZBI is a caregiver-reported instrument used widely to evaluate caregiver burden associated with AD and other diseases such as multiple sclerosis, congestive heart failure, and cancer. Items on the ZBI-12 assess caregiver stress, time available for self, and the impact of caring on the caregiver's social life. Responses are provided on a 5-point Likert scale (never=0, nearly always=4). The ZBI-12 total score has a range of 0 to 48, with higher scores indicating greater caregiver burden.

    Time frame: Baseline, Up to 5 Years

  7. Change from Baseline Over Time (Assessed Semi-Annually) in Living Situation as Assessed by the Participant Lifestyle Questionnaire (P-LSQ)

    The P-LSQ is a brief, sponsor-created questionnaire used to collect supplementary data regarding participants' living environment, home healthcare needs, and driving status that is not captured elsewhere.

    Time frame: Baseline, Up to 5 Years

  8. Change from Baseline Over Time (Assessed Semi-Annually) in Home Healthcare as Assessed by the P-LSQ

    Time frame: Baseline, Up to 5 Years

  9. Change from Baseline Over Time (Assessed Semi-Annually) in Driving Status as Assessed by the P-LSQ

    Time frame: Baseline, Up to 5 Years

07

Study locations

1 of 1 sites recruiting
  • Rehabilitation & Neurological Services
    Huntsville, Alabama 35805-4046, United States
    Recruiting
    • Belinda Savage-Edwards · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2031, 79 months after the start.

Of 41 industry-sponsored observational studies under Alzheimer Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 79 months is above that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Feb 2033 → May 2031 and completion Feb 2033 → May 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 22, 2024
StartActual
Oct 7, 2024
Primary completionEst.
May 2031was Feb 2033
CompletionEst.
May 2031was Feb 2033
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 2033→May 2031
Nov 3, 2026
Study completion
Feb 2033→May 2031
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Primary completion Feb 2033→May 2031
    Study completion Feb 2033→May 2031
    + 1 other change: verification date
  2. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06566170
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Oct 7, 2024
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Contact
clinical_inquiry_hub@lilly.com
1-317-615-4559
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion